CroíValve Announces the Appointment of Jaime Wheeler as Chief Executive Officer
Veteran structural heart executive to lead the company through its next phase of clinical and commercial growth
CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare executive with more than 25 years of experience driving innovation at the intersection of clinical excellence and business strategy. Previously, Jaime served as the Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves at Edwards Lifesciences. There, she was instrumental in bringing multiple breakthrough therapies to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728639143/en/ Jaime Wheeler, Chief Executive Officer, CroíValve
CroíValve recently announced the expansion of its TANDEM II study, a US and EU based prospective, multicenter study to evaluate the safety and performance of the DUO™ Adapt System in patients with severe or greater symptomatic TR.
